Draft:Formation Bio
 | Review waiting, please be patient.
This may take 5 weeks or more, since drafts are reviewed in no specific order. There are 2,572 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
This draft is not written from a neutral point of view. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Comment: WP:ORGTRIV and WP:CHURN does very little to denote notability Sulfurboy (talk) 20:21, 14 August 2026 (UTC)
| Type | Private |
|---|---|
| Industry | Drug development |
| Founded | 2016 |
| Founder | Benjamine Liu; Linhao Zhang |
| Headquarters | New York, NY |
| Website | formation |
Summary
[edit]Formation Bio is a biotechnology company that acquires and develops clinical-stage drug candidates, using artificial intelligence in its research and operations.[1][2] The company, headquartered in New York City, was founded in 2016 as TrialSpark.[3]
History
[edit]Benjamine Liu and Linhao Zhang founded the company in 2016.[1][2] Liu had studied machine learning applications for identifying neurodegenerative-disease drug candidates as a computational biologist at the University of Oxford, and has said the company grew out of the difficulty he encountered advancing a candidate through clinical development.[4] Operating initially as TrialSpark, the company built software to run clinical trials before rebranding as Formation Bio and focusing on acquiring and in-licensing clinical-stage drug candidates itself.[3]
In 2019, Liu and Zhang partnered with former Novartis chief executive Joseph Jimenez to found Aditum Bio, a venture firm that acquired and developed drug candidates through separate companies, with Formation Bio as a minority investor.[4]
The company was named to CNBC's Disruptor 50 list and Fierce Biotech's Fierce 15 in 2025, and received Endpoints News's Endpoints 11 award in 2024.[1][5][6]
Business model
[edit]Formation Bio in-licenses drug candidates from pharmaceutical companies and biotechnology firms and develops them using an AI model.[4][6][7] After a drug achieves published results in Phase 2 or 3 trials, the company outlicenses or partners the asset for further development and commercialization with pharmaceutical partners.[1][4] The company’s pipeline includes two clinical-stage programs, BLKR201 for inflammation and sprifermin for knee osteoarthritis, along with a preclinical autoimmune-disease candidate, KMR301.[8]
Partnerships
[edit]Formation Bio, OpenAI and Sanofi announced a collaboration in May 2024 to build AI models for drug development.[9] The partnership's product, an AI tool for clinical trial patient recruitment called Muse, launched in November 2024.[1][5]
Funding
[edit]Formation Bio has raised more than $600 million from investors including Sequoia Capital, Michael Moritz, Thrive Capital and Andreessen Horowitz.[1][5] It raised a $372 million Series D round in June 2024.[7][10] In June 2025, the company licensed gusacitinib, an oral JAK/SYK inhibitor then in Phase 3 trials, to Sanofi in a deal worth up to €545 million.[11]
References
[edit]- 1 2 3 4 5 6 Castillo, Michelle (2025-06-10). "37. Formation Bio". CNBC. Retrieved 2026-09-24.
- 1 2 Anderson, Stuart (August 10, 2022). "Immigrant Ben Liu And TrialSpark Revolutionizing Clinical Trials". Forbes.
{{cite news}}: CS1 maint: url-status (link) - 1 2 Waldron, James (2024-06-26). "AI-focused Formation bags $372M series D to license more drugs". www.fiercebiotech.com. Retrieved 2026-09-24.
- 1 2 3 4 Feldman, Amy (April 16, 2026). "This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster". Forbes.
{{cite news}}: CS1 maint: url-status (link) - 1 2 3 Masson, Gabrielle (2025-09-22). "Fierce Biotech's 2025 Fierce 15". www.fiercebiotech.com. Retrieved 2026-09-24.
- 1 2 "Endpoints 11 winner Formation Bio: A Silicon Valley-fueled unicorn aiming to be the next Roivant — or more". Endpoints News. Retrieved 2026-09-24.
- 1 2 Wiggers, Kyle (2024-06-26). "Formation Bio raises $372M to boost drug development with AI". TechCrunch. Retrieved 2026-09-24.
- ↑ Pecci, Alexandra (August 12, 2026). "Formation Bio taps Biogen, Pfizer alum to tackle R&D's 'boring middle'". BioPharma Dive. Retrieved 2026-09-24.
{{cite web}}: CS1 maint: url-status (link) - ↑ "Sanofi partners with OpenAI, Formation Bio on AI-driven drug development". Reuters. 2024-05-21. Retrieved 2026-09-24.
- ↑ Kasianov, Roman (2024-06-26). "Formation Bio Secures $372 Million Series D Funding for AI-Driven Drug Development". www.biopharmatrend.com. Retrieved 2026-09-24.
- ↑ Waldron, James (2025-06-23). "Sanofi signs $626M deal to explore Formation's JAK/SYK inhibitor". www.fiercebiotech.com. Retrieved 2026-09-24.
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.